### 2.2.1 In vitro / physicochemical data

A literature search was carried out to collect available information on physicochemical properties of triazolam. The obtained information from the literature is summarized in the table below and is used for model building.

| **Parameter**          | **Unit** | **Literature**                                               | **Description**                                              |
| :--------------------- | -------- | ------------------------------------------------------------ | ------------------------------------------------------------ |
| Molecular weight       | g/mol    | 343.21 ([drugbank.ca](#5-References))                       | Molecular weight                                             |
| pK<sub>a</sub> (basic) |          | 1.52 ([Konishi 1982](#5-References))                        | Acid dissociation constant                                   |
| logP                   |          | 2.42 ([drugbank.ca](#5-References))                         | Partition coefficient between octanol and water              |
| logD                   |          | 1.63 ([Greenblatt 1983a](#5-References))                    | Partition coefficient between octanol and water at physiological pH |
| f<sub>u</sub>          |          | 0.099 ± 0.015<sup>a</sup> ([Jochemsen 1983](#5-References)); 0.11 ([Eberts 1981](#5-References)); 0.174 ± 0.020<sup>a</sup> ([Friedman 1988](#5-References)); 0.188 ± 0.139<sup>a</sup> ([Ochs 1987](#5-References)); 0.213 [0.193 - 0.264]<sup>b</sup> ([Greenblatt 1983b](#5-References)); 0.229 [0.204 - 0.259]<sup>c</sup> ([Greenblatt 1983b](#5-References)) | Fraction unbound in human plasma of healthy adults           |
| Water solubility       | mg/L     | 4.53 ([drugbank.ca](#5-References))                         | Estimated solubility in water                                |

<sup>a</sup> mean ± standard deviation

<sup>b</sup> mean [range] in young males

<sup>c</sup> mean [range] in young females

### 2.2.2 Clinical data

A literature search was carried out to collect triazolam PK data in healthy adults. 

The following publications were found and used for model building and evaluation:

| Publication                            | Study description                                            |
| :------------------------------------- | :----------------------------------------------------------- |
| [Friedman 1986](#5-References)        | PO single dose administration of 0.5 mg                      |
| [Friedman 1988](#5-References)        | PO single dose administration of 0.5 mg                      |
| [Greenblatt 1989](#5-References)      | PO single dose administration of 0.25 mg                     |
| [Greenblatt 1991](#5-References)      | PO single dose administration of 0.125 mg                    |
| [Greenblatt 2000](#5-References)      | PO single dose administration of 0.25 mg                     |
| [Greenblatt 2004](#5-References)      | PO single dose administration of 0.25 mg                     |
| [Hukkinen 1995](#5-References)        | PO single dose administration of 0.25 mg                     |
| [Lilja 2000](#5-References)           | PO single dose administration of 0.25 mg                     |
| [Kroboth 1985](#5-References)         | IV single dose administration of 0.25 mg and PO single dose administration of 0.25 mg |
| [O'Connor-Semmes 2001](#5-References) | PO single dose administration of 0.25 mg                     |
| [Ochs 1984](#5-References)            | PO single dose administration of 0.5 mg                      |
| [Phillips 1986](#5-References)        | PO single dose administration of 0.5 mg                      |
| [Smith 1987](#5-References)           | IV single dose administration of 0.125 mg, 0.25 mg, 0.5 mg, 0.75 mg, and 1 mg |
| [Varhe 1994](#5-References)           | PO single dose administration of 0.25 mg                     |
| [Varhe 1996a](#5-References)          | PO single dose administration of 0.25 mg                     |
| [Varhe 1996b](#5-References)          | PO single dose administration of 0.25 mg                     |
| [Varhe 1996c](#5-References)          | PO single dose administration of 0.25 mg                     |
| [Villikka 1997](#5-References)        | PO single dose administration of 0.5 mg                      |
| [Villikka 1998](#5-References)        | PO single dose administration of 0.5 mg                      |
| [von Moltke 1996](#5-References)      | PO single dose administration of 0.125 mg                    |

